Immunomodulation of experimental pulmonary fibrosis by intravenous immunoglobulin (IVIG)

References

• Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001; 345(7)517–525
   PubMed Web of Science ®Google Scholar
• Ong CJ, Ip S, Teh SJ, et al. A role for T helper 2 cells in mediating skin fibrosis in tight-skin mice. Cell Immunol 1999; 196(1)60–68
   PubMedGoogle Scholar
• Fertin C, Nicolas JF, Gillery P, Kalis B, Banchereau J, Maquart FX. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol 1991; 37(8)823–829
   PubMed Web of Science ®Google Scholar
• Gillery P, Fertin C, Nicolas JF, et al. Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis. FEBS Lett 1992; 302(3)231–234
   PubMed Web of Science ®Google Scholar
• Sempowski GD, Beckmann MP, Derdak S, Phipps RP. Subsets of murine lung fibroblasts express membrane-bound and soluble IL-4 receptors. Role of IL-4 in enhancing fibroblast proliferation and collagen synthesis. J Immunol 1994; 152(7)3606–3614
   PubMed Web of Science ®Google Scholar
• Pablos JL, Everett ET, Harley R, LeRoy EC, Norris JS. Transforming growth factor-beta 1 and collagen gene expression during postnatal skin development and fibrosis in the tight-skin mouse. Lab Invest 1995; 72(6)670–678
   PubMedGoogle Scholar
• Peltonen J, Kahari L, Jaakkola S, et al. Evaluation of transforming growth factor beta and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J Invest Dermatol 1990; 94(3)365–371
   PubMedGoogle Scholar
• Broekelmann TJ, Limper AH, Colby TV, McDonald JA. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 1991; 88(15)6642–6646
   PubMed Web of Science ®Google Scholar
• McCormick LL, Zhang Y, Tootell E, Gilliam AC. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human scleroderma. J Immunol 1999; 163(10)5693–5699
   PubMed Web of Science ®Google Scholar
• Ong C, Wong C, Roberts CR, Teh HS, Jirik FR. Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998; 28(9)2619–2629
   PubMed Web of Science ®Google Scholar
• Ryu JH, Colby TV, Hartman TE. Idiopathic pulmonary fibrosis: Current concepts. Mayo Clin Proc 1998; 73(11)1085–1101
   PubMedGoogle Scholar
• Kolb M, Margetts PJ, Sime PJ, Gauldie J. Proteoglycans decorin and biglycan differentially modulate TGF-beta-mediated fibrotic responses in the lung. Am J Physiol Lung Cell Mol Physiol 2001; 280(6)L1327–L1334
   PubMed Web of Science ®Google Scholar
• Pittet JF, Griffiths MJ, Geiser T, et al. TGF-beta is a critical mediator of acute lung injury. J Clin Invest 2001; 107(12)1537–1544
   PubMed Web of Science ®Google Scholar
• Schirner M, Hoffmann J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998; 4(5)1331–1336
   PubMed Web of Science ®Google Scholar
• Sausville EA, Peisach J, Horwitz SB. Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry 1978; 17(14)2740–2746
   PubMed Web of Science ®Google Scholar
• Sausville EA, Stein RW, Peisach J, Horwitz SB. Properties and products of the degradation of DNA by bleomycin and iron(II). Biochemistry 1978; 17(14)2746–2754
   PubMedGoogle Scholar
• Burger RM, Peisach J, Horwitz SB. Activated bleomycin. A transient complex of drug, iron, and oxygen that degrades DNA. J Biol Chem 1981; 256(22)11636–11644
   PubMed Web of Science ®Google Scholar
• Umezawa H, Takeuchi T, Hori S, Sawa T, Ishizuka M. Studies on the mechanism of antitumor effect of bleomycin of squamous cell carcinoma. J Antibiot (Tokyo) 1972; 25(7)409–420
   PubMed Web of Science ®Google Scholar
• Onuma T, Holland JF, Masuda H, Waligunda JA, Goldberg GA. Microbiological assay of bleomycin: Inactivation, tissue distribution, and clearance. Cancer 1974; 33(5)1230–1238
   PubMedGoogle Scholar
• Snider GL, Hayes JA, Korthy AL. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin: Pathology and stereology. Am Rev Respir Dis 1978; 117(6)1099–1108
   PubMedGoogle Scholar
• Bayry J, Thirion M, Misra N, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci 2003; 24(Suppl 4)S217–S221
   PubMedGoogle Scholar
• Levy Y, Sherer Y, Langevitz P, et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin—a preliminary report. Clin Rheumatol 2000; 19(3)207–211
   PubMedGoogle Scholar
• Lister RK, Jolles S, Whittaker S, et al. Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 2000; 43(2 Pt 2)403–408
   PubMedGoogle Scholar
• Levy Y, Amital H, Langevitz P, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open-label study. Arthritis Rheum 2004; 50(3)1005–1007
   PubMed Web of Science ®Google Scholar
• Campbell DE, Georgiou GM, Kemp AS. Pooled human immunoglobulin inhibits IL-4 but not IFN-gamma or TNF-alpha secretion following in vitro stimulation of mononuclear cells with Staphylococcal superantigen. Cytokine 1999; 11(5)359–365
   PubMedGoogle Scholar
• Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000; 94(2)99–104
   PubMed Web of Science ®Google Scholar
• Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O. The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 2002; 46(6)1689–1690
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Andreassen IH, Hogasen K, Hack CE, Harboe M. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol Immunol 1997; 34(10)719–729
   PubMedGoogle Scholar
• Lutz HU, Stammler P, Bianchi V, et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004; 103(2)465–472
   PubMedGoogle Scholar
• Grande JP. Role of transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med 1997; 214(1)27–40
   PubMed Web of Science ®Google Scholar
• Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104(Suppl 1)10–20
   PubMedGoogle Scholar
• Shapiro S, Shoenfeld Y, Gilburd B, Sobel E, Lahat N. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 2002; 95(9)2032–2037
   PubMed Web of Science ®Google Scholar
• Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology 2001; 62(3)133–137
   PubMedGoogle Scholar
• Kaminski N, Allard JD, Pittet JF, et al. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis. Proc Natl Acad Sci U S A 2000; 97(4)1778–1783
   PubMed Web of Science ®Google Scholar
• Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A 2002; 99(9)6292–6297
   PubMed Web of Science ®Google Scholar
• Ortiz LA, Gambelli F, McBride C, et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci U S A 2003; 100(14)8407–8411
   PubMed Web of Science ®Google Scholar
• Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 2002; 83(3)111–119
   PubMed Web of Science ®Google Scholar
• Bayry J, Lacroix-Desmazes S, Delignat S, et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 2003; 48(12)3497–3502
   PubMedGoogle Scholar
• Mullbacher A, Lobigs M, Hla RT, Tran T, Stehle T, Simon MM. Antigen-dependent release of IFN-gamma by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cell lysis. J Immunol 2002; 169(1)145–150
   PubMedGoogle Scholar
• Ahn JH, Park SM, Cho HS, et al. Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-kappaB-dependent gene expression. J Biol Chem 2001; 276(50)47100–47106
   PubMedGoogle Scholar
• Prasad NK, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161(7)3781–3790
   PubMed Web of Science ®Google Scholar
• Ronda N, Gatti R, Giacosa R, et al. Antifibroblast antibodies from systemic sclerosis patients are internalized by fibroblasts via a caveolin-linked pathway. Arthritis Rheum 2002; 46(6)1595–1601
   PubMedGoogle Scholar
• Ronda N, Raschi E, Testoni C, et al. Anti-fibroblast antibodies in systemic sclerosis. Isr Med Assoc J 2002; 4(11)858–864
   PubMedGoogle Scholar
• Shoenfeld Y, Krause I. i.v. IG for autoimmune, fibrosis, and malignant conditions: Our experience with 200 patients. J Clin Immunol 2004; 24(2)107–114
   PubMed Web of Science ®Google Scholar
• Amital H, Rewald E, Levy Y, et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis 2003; 62(2)175–177
   PubMedGoogle Scholar
• Aharon A, Levy Y, Bar-Dayan Y, et al. Successful treatment of early secondary myelofibrosis in SLE with IVIG. Lupus 1997; 6(4)408–411
   PubMedGoogle Scholar